Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Conditions:   Stage III Hepatocellular Carcinoma AJCC v8;   Stage IIIA Hepatocellular Carcinoma AJCC v8;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IVA Hepatocellular Carcin oma AJCC v8;   Stage IVB Hepatocellular Carcinoma AJCC v8 Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Sorafenib Sponsors:   University of California, San Francisco;   Bayer;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials